irganox 1010 has been researched along with phosphites in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, S; Marcato, B; Scalia, S; Vianello, M | 1 |
| Abolhassni, J; Farajzadeh, MA; Jamshidi, MA; Mogaddam, MRA; Naebi, M | 1 |
| Bercu, J; Binazon, O; Broschard, T; Bruen, U; Callis, CM; Cruz, MT; Dolan, DG; Erexson, GL; Giddings, A; Glowienke, S; Li, K; Martin, EA; Masuda-Herrera, M; Nagao, LM; Parris, P; Stanard, B; Stults, CLM; Whelan, G | 1 |
3 other study(ies) available for irganox 1010 and phosphites
| Article | Year |
|---|---|
Migration of antioxidant additives from various polyolefinic plastics into oleaginous vehicles.
Topics: Antioxidants; Butylated Hydroxytoluene; Drug Packaging; Pharmaceutical Vehicles; Phosphites; Plastics; Polyenes | 2003 |
In-process prepared deep eutectic solvent based homogeneous liquid-liquid microextraction for the determination of irgaphos 168 and irganox 1010 in polypropylene packed drinks.
Topics: Beverages; Butylated Hydroxytoluene; Food Contamination; Liquid Phase Microextraction; Phosphites; Polypropylenes; Product Packaging; Solvents; Water Pollutants, Chemical | 2020 |
Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studies.
Topics: Animals; Benzhydryl Compounds; Butylated Hydroxytoluene; Cricetinae; Decision Trees; Drug Contamination; Drug Packaging; Humans; Mice; Patient Safety; Pharmaceutical Preparations; Phenols; Phosphites; Rats; Risk Assessment; Toxicity Tests; Toxicokinetics | 2020 |